Skip to main content
. 2017 May 10;255(8):1651–1660. doi: 10.1007/s00417-017-3685-y

Fig. 3.

Fig. 3

Proportion of eyes with choroidal neovascularization at each visit from the time of first ranibizumab 0.5 mg injection until 4 years (eyes analysis population) *After the first injection of ranibizumab (± 1 week for 1 and 2 months, ± 2 weeks for 3 and 6 months, ± 1 month for 9 months, and ±2 months for all other time points)